Kissei Pharmaceutical Co., Ltd.
Research Kissei Pharmaceutical Co., Ltd. (4547.T) on Bullrun: market cap JPY 159.01B, P/E 11.3, dividend yield 5.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4547.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyJPY
- Market capJPY 159.01B
- P/E11.3
- Dividend yield5.4%
- Financial periodFY2026
- RevenueJPY 97.41B
- Revenue growth10.3%
- Net incomeJPY 13.78B
- Free cash flow-JPY 7.12B
- Gross margin47.0%
Valuation Snapshot
latest market cap is JPY 159.01B; P/E is 11.3; dividend yield is 5.4%.
Peer valuation comparison
Latest P/E is 11.34x versus a Healthcare sector median of 21.69x (47.7% below).
Latest dividend yield is 5.37% versus a Healthcare sector median of 2.41% (122.8% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | JPY 97.41B | JPY 13.78B | -JPY 7.12B | 47.0% | 331.54 | JPY 29.06B | JPY 1.25B | JPY 230.15B |
| FY2025 | JPY 88.33B | JPY 11.96B | JPY 1.49B | 49.9% | 274.21 | JPY 25.17B | JPY 1.28B | JPY 209.00B |
| FY2024 | JPY 75.58B | JPY 11.16B | -JPY 3.51B | 49.4% | 246.61 | JPY 22.89B | JPY 1.34B | JPY 220.03B |
| FY2023 | JPY 67.49B | JPY 10.53B | -JPY 9.23B | 48.0% | 228.31 | JPY 25.89B | JPY 1.49B | JPY 193.90B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 159.01B | 11.3 | 3.4% | 130 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 130 JPY, yield 5.4%.
| Year | Dividends/share |
|---|---|
| FY2026 | 205 JPY |
| FY2025 | 115 JPY |
| FY2024 | 86 JPY |
| FY2023 | 81 JPY |
About Kissei Pharmaceutical Co., Ltd.
Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan and internationally. It offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Kissei Pharmaceutical Co., Ltd.'s market cap?
Kissei Pharmaceutical Co., Ltd.'s market capitalization is JPY 159.01B.
What is Kissei Pharmaceutical Co., Ltd.'s P/E ratio?
Kissei Pharmaceutical Co., Ltd.'s price-to-earnings (P/E) ratio is 11.3.
Does Kissei Pharmaceutical Co., Ltd. pay a dividend?
Kissei Pharmaceutical Co., Ltd. has a dividend yield of 5.4%.
What does Kissei Pharmaceutical Co., Ltd. do?
Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan and internationally. It offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia.